Poseida Therapeutics

Website:poseida.com
Location:San Diego, CA United States
Revenue:N/A
Industry:Biotech
Founded:2015
Lead Investor(s):Longitude Capital
Press

Current Growjo Ranking

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac? DNA Modification System, TAL-CLOVER? and Cas-CLOVER? site-specific nucleases, and Footprint-Free? Gene Editing (FFGE). For more information, visit www.poseida.com.

keywords:Automotive,Biotechnology,Healthcare,Pharmaceuticals

63

Number of Employees

N/A

Revenue (est)

11

Current Jobs

43%

Employee Growth %

$226.5M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Poseida Therapeutics News

13-Mar-19 - Adopt a moratorium on heritable genome editing

J. Keith Joung (J.K.J.) has financial interests in Beam Therapeutics, ... EpiLogic Therapeutics, Pairwise Plants, Poseida Therapeutics, and

13-Feb-19 - Poseida Therapeutics Announces Notice of Allowance for New

13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene

4-Jan-19 - Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments

Poseida Therapeutics, which is testing CAR-T cell therapies for blood-borne and solid tumor cancers, has laid the groundwork for an initial

Poseida Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-12-17$30.0MAMalin Corporation plcArticle
2015-12-29$23.0MUndisclosedArticle
2018-04-05$30.0MBLongitude CapitalArticle

Poseida Therapeutics Executive Hires

DateNameTitleReference
2017-01-04Debra GessnerVP Regulatory AffairsArticle
2018-02-06Martin GiedlinVice President, Technical OperationsArticle
2018-03-01Mark Gergenchief business officer and chief financial officer.Article
2018-10-10Marcy GrahamVice President, Corporate AffairsArticle